PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Worldwide Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies and Age Groups: Paving the Way for Innovative Cancer Therapies
Version 1
: Received: 29 September 2023 / Approved: 30 September 2023 / Online: 30 September 2023 (05:37:35 CEST)
How to cite:
Jankovic, M.; Knezevic, T.; Jovanovic, T.; Todorovic-Balint, M.; Djunic, I.; Mihaljevic, B.; Knezevic, A. Worldwide Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies and Age Groups: Paving the Way for Innovative Cancer Therapies. Preprints2023, 2023092154. https://doi.org/10.20944/preprints202309.2154.v1
Jankovic, M.; Knezevic, T.; Jovanovic, T.; Todorovic-Balint, M.; Djunic, I.; Mihaljevic, B.; Knezevic, A. Worldwide Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies and Age Groups: Paving the Way for Innovative Cancer Therapies. Preprints 2023, 2023092154. https://doi.org/10.20944/preprints202309.2154.v1
Jankovic, M.; Knezevic, T.; Jovanovic, T.; Todorovic-Balint, M.; Djunic, I.; Mihaljevic, B.; Knezevic, A. Worldwide Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies and Age Groups: Paving the Way for Innovative Cancer Therapies. Preprints2023, 2023092154. https://doi.org/10.20944/preprints202309.2154.v1
APA Style
Jankovic, M., Knezevic, T., Jovanovic, T., Todorovic-Balint, M., Djunic, I., Mihaljevic, B., & Knezevic, A. (2023). Worldwide Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies and Age Groups: Paving the Way for Innovative Cancer Therapies. Preprints. https://doi.org/10.20944/preprints202309.2154.v1
Chicago/Turabian Style
Jankovic, M., Biljana Mihaljevic and Aleksandra Knezevic. 2023 "Worldwide Human Cytomegalovirus Oncoprotection across Diverse Populations, Tumor Histologies and Age Groups: Paving the Way for Innovative Cancer Therapies" Preprints. https://doi.org/10.20944/preprints202309.2154.v1
Abstract
The oncogenicity of the human cytomegalovirus (CMV) is debated to this day. In recent years, mounting evidence addresses an anti-cancer effect via T cell-mediated CMV-targeted tumor de-struction. However, the data mostly comes from single-center studies and in vitro experiments. Broad geographic coverage is required to offer a global perspective. This study examined the correlation between country-specific CMV seroprevalence (n=73) and age-standardized inci-dence rates for 34 tumors using data obtained from the International Agency for Research on Cancer of the World Health Organization. The association between CMV and cancer incidences in 10-year age increments was also analyzed. The study revealed a worldwide inverse correlation between CMV seroprevalence and incidences of 88.2% tumors. Notably, this inverse link persists for all cancers combined (Spearman’s ρ= -0.732, p= 0.001). An antithetical and significant correlation is also observed in particular age groups for the vast majority of tumors. Our results corroborate the conclusions of previous studies and indicate that this phenomenon holds true on a global scale. It applies to a wide spectrum of cancer histologies, suggesting a common under-lying mechanism – CMV-stimulated T cell tumor targeting. Although these results further advance the notion of CMV-based therapies, further in-depth investigation of host-virus interactions is warranted.
Keywords
Cytomegalovirus; oncogenesis; oncoprotection; cancer; global; T cell
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
